Alternatively, in patients who failed or did not tolerated anakinra, canakinumab and rilonacept monoclonal antibodies against IL-1β, might be alternative therapeutic options [11,36-38]. To our knowledge, there are no approved biologic disease-modifying antirheumatic drugs for aseptic meningitis in ADs. The gene discussed is IL1B; the disease is aseptic meningitis.